Preliminary Results

RNS Number : 4476X
Inspiration Healthcare Group PLC
30 April 2019
 

 

30 April 2019

Inspiration Healthcare Group plc

("Inspiration Healthcare" or the "Group")

 

Preliminary Results for the year ended 31 January 2019

 

Inspiration Healthcare Group plc (AIM: IHC), the global medical device company, today announces its preliminary results for the twelve months ended 31 January 2019 ("FY2019").

 

Financial highlights:

·      EBITDA1 up 13% to £1.65m (FY2018: £1.45m)

·      Revenue stable at £15.5m (FY2018: £15.5m), constrained by well publicised industry wide regulatory delays

·      Operating Profit of £1.2m in line with expectations (FY2018: £1.2M)

·      Record International sales up 12% to £5.4m (FY2018: £4.8m), with the strongest growth coming from the USA with sales up 71%

·      New products launched generated revenues of £1.4m in FY2019, showcasing the Group's well-established product development pipeline

·      Cash remains strong, ending the year at £2.5m (2018: £2.1m)

 

1 Earnings before interest, taxation, depreciation, amortisation and share based payments ("EBITDA")

See Operating and Financial Review for reconciliation

 

Operational highlights:

 

·      Launched the Alphacore5 Patient Warming System, which provides safe and controlled warming to assist in the maintenance of normothermia

·      The Group received its largest ever order for a Patient Warming System, with 500 Alphacore5 systems being shipped to over 200 hospitals for treating newborn babies throughout Poland

·      Strong product pipeline with a Licence Agreement signed with a major US university to allow us to develop a novel respiratory device ("Project Wave")

·      Received certification to Medical Device Single Audit Programme in 4 countries (USA, Canada, Japan and Australia) and ISO 13485:2016, which reduces the need for external audits, positioning the Company well to increase sales in these territories

·      Strengthened senior management team with Head of Operations appointment

·      Won a Queens's Award for Enterprise

 

Neil Campbell, Chief Executive Officer, said today: "I am pleased that we have achieved our profit expectations for a year in which the regulatory issues that consume our industry provided us with many challenges and constrained our revenue growth.  The investment we have made in key areas of our business has started to pay off with 9% of revenues coming from new products, including the recently launched Patient Warming System, and 12% growth in international revenues.  We have strengthened our management team and passed two new major Quality Management System audits which will allow us to capitalise on recent international growth.  With a strong order book at the beginning of the new year, I am confident that we are well placed to achieve our expectations for the year ahead."

 

Enquiries:

 

Inspiration Healthcare Group plc

Neil Campbell, Chief Executive Officer

Mike Briant, Chief Financial Officer

Tel: 01455 840555

 

Nominated Adviser & Broker

Cenkos Securities plc

Mark Connelly

Cameron MacRitchie 

Tel: 0207 397 8900

 

Cadogan PR                                                                                         

Alex Walters

Tel: 07771 713608

               

About Inspiration Healthcare

 

Inspiration Healthcare (AIM: IHC) is a global supplier of medical technology for critical care, operating theatre and other medical applications. The Company provides high quality innovative products to patients and caregivers around the world that help to improve patient outcomes and efficiencies of healthcare organisations with patient focused customer service and technical support.

 

The Company's own brand of critical care solutions span non-invasive respiratory management, thermoregulation and diagnostics, and patient warming for newborns through to adults in intensive care and the operating theatre, whilst the distribution business supplies solutions to support specialised surgical procedures and infusion therapies.

 

Present in over 50 countries worldwide, Inspiration Healthcare's success has been built on continuous innovation, excellent customer service and an inherent commitment to improving the quality of life of patients, working in close collaboration with key opinion leaders and stakeholders in the clinical and medical community across the globe.

Further information on Inspiration Healthcare can be seen at www.inspiration-healthcare.com.

 

Chairman's Report

 

The Group is one full of energy and positivity and a desire to make a genuine difference to the outcome of some of the most fragile patients and therefore I am pleased to write to you again on another year of progress at Inspiration Healthcare Group plc. 

 

For the year ended 31 January 2019 ("FY2019"), we met our operating profit expectations at £1.2 million (FY2018: £1.2 million) with EBITDA1 improving by 13% from £1.45 million to £1.65 million.  This was achieved through increasing gross margin from 44% in FY2018 to 45% in FY2019, prudent management of overheads and the timing of investment - trying to balance the impact on profits with the benefit for long term growth. Underlying diluted Earnings per Share ("EPS")2 declined by 0.06 pence per share, due to a slightly higher tax charge.

 

The Group's revenue was flat at £15.5 million and although this is disappointing, it is the first time after 15 years of successive revenue growth and needs to be seen in the context of the wide changes taking place within our industry and the current global trade tensions and uncertainties.   Despite these uncertainties it is notable that we increased our International revenue by 12%.  Changing our distributor in the USA has had a positive impact at the end of the year and we expect this new relationship to have long term benefits for other products that we will seek market authorisation for.

 

The year has also been difficult due to the continuing regulatory hurdles that are engulfing the industry.  It has been widely reported by many commentators that the regulations are changing rapidly and causing issues within the industry as a whole.  As at end of March 2019, the number of Notified Bodies for Medical Devices was 58, falling from 75 in 2013, putting unprecedented strain on those that remain.  It is therefore noteworthy that we have invested in our staff and systems and continue to do so.  This has put us in a strong position to ensure compliance to these new regulations and also to minimise the impact that Brexit will have on our medical devices being placed on the market in the UK and in the EU.

 

We could not have estimated the true impact of the regulatory delays caused by these changes, the knock-on effect of registering products, supplying customers, and building the supply chain.  Clearly these were greater than we first thought.  However, we have new products launched and registered in most key markets and have been making plans as to how to maximise revenues with our distribution partners to make these products a success.

 

Our investment in our management team has continued this year to create a strong platform for growth.  Our management team has been strengthened with the new position of Head of Operations, improving our efficiencies in this core area of our business as well as putting in place the building blocks for further expansion.  We welcome Nigel Weston to the company in this new role.

 

1 Earnings before interest, taxation, depreciation, amortisation and share based payments

2 EPS before significant prior year tax amendments

See Operating and Financial Review for reconciliation

 

As an international business importing and exporting around the world, Brexit took up substantial time for contingency planning regardless of the outcome.  As many others have noted, the continued lack of clarity on Brexit was unhelpful, stretching resources that could have been utilised elsewhere to the benefit of the business.  We naturally increased our stock holding and worked through issues with suppliers, principals and distributors alike, and of course we worked closely with the Department of Health and Social Care ensuring that regardless of the outcome we would be able to supply the NHS with life-saving medical devices.  We are confident that we have done everything we can to prepare the Group for any scenario and will continue to do so.

 

Last year we stated that we would continue to invest in R&D and we have continued to do so.  Although overall spend declined from 6.2% of revenue in FY2018 to 4.1% in FY2019 due to capital spend being lower because of timing of certain projects, I can report that we increased our investment in in-house R&D staff resources by 39% in FY2019.  Bringing more resources in house will mean we are more efficient in the future.

 

Employees

I am proud of the way our staff rose to the challenges during the year.  They tenaciously chased opportunities, worked hard to realise those that were achievable and acted thoroughly professionally throughout the difficult times. We will continue to invest in our staff as our most valuable asset and create an environment they can be proud to work in. On behalf of the Board I thank them sincerely for their endeavours.  

 

Outlook

We now have key new products registered in over 40 countries and our sales team are now working hard with our distributors to establish these products, further building on the current sales that have already achieved £1.4 million in the last financial year.

 

We will continue to implement our strategy to develop the Group into world leader in Neonatal Intensive Care through organic growth and acquisitions.  The Group continues to look for acquisitions both of technology / products and companies, although it is difficult to predict the exact timing of any of these opportunities. 

 

The opportunity from our recent licence agreement with a major US based university ("Project Wave") is extremely exciting. It reflects our approach to developing disruptive technologies in neonatal intensive care.

 

We have a strong R&D pipeline and with the strengthening of management and the accreditation to Medical Device Single Audit Program ("MDSAP") and ISO 13485:2016, we have positive times ahead.  We expect to benefit from the improvement in higher margins from our new products. The new year has started with a very healthy order book and we look forward to maintaining this momentum to deliver double digit revenue growth.

 

Mark Abrahams

Chairman

30th April 2019

 

Going Concern

 

The Group has prepared a budget for the year ended 31 January 2019 and financial projections for the following two years. Having due consideration of these projections and available cash at 31 January 2019 of £2.5 million, it is the opinion of the Board that the Group has adequate resources to continue to trade as a going concern.

 

Operating and Financial Review

 

Our revenue for the year ended 31 January 2019 ("FY2019") was £15.5 million, in line with FY2018 owing to the well-publicised regulatory delays for new products and their EC certification which have constrained revenue growth.

 

EBITDA1 increased by 13% to £1.65 million (FY2018: £1.45 million). Operating profit was £1.2 million in line with FY2018 and our expectations. Operating margin for FY2019 was 7.8% (FY2018:7.8%). Profit after tax was £1.1 million, lower than FY2018 (£1.2 million) due to a higher year on year net taxation charge. Diluted EPS was 3.56p per share (FY2018: 3.98p). Underlying diluted EPS2 decreased by 1.7% to 3.40p per share (FY2018: 3.46p).

 

Revenue

During the year our plans to launch new products were frustrated by significant delays experienced in obtaining an updated Quality Management System certificate and a CE Mark approval for our upgraded Patient Warming System, the AlphaCore5, which delayed product registrations. The AlphaCore5 patient warming system ("PWS") was consequently not launched until July meaning loss of momentum which hampered second half revenue growth. As in prior years, revenues were still weighted towards the second half ("H2") which accounted for £8.1 million (FY2018: £8.3 million) or 52% of full year revenues.

 

Our international revenue grew by 12.4% to £5.4 million, with particularly strong growth in North America (up 71%) due to increased sales of the Tecotherm product range. Domestic revenue declined by 5.6%, largely due to a reduction in capital sales of ventilators.

 

Products developed in-house and launched within the last 18 months include the Inspire rPAP driver, the PWS, the upgraded LifeStart and the Unique+ CFM. Revenues generated from these products in FY2019 amount to £1.4 million. These new products accounted for 9% of FY2019 revenue which, together with Tecotherm revenue growth, offset the decline in the variable capital element of our Distributed Products in Critical Care and the gradual decline of our older licenced products (including Inspire nCPAP).

 

Market Sectors

 

Critical Care £10.7 million, -5% year on year

Our Critical Care sector declined by 5%, largely due to the decline in capital sales of ventilators and Inspire nCPAP mentioned above. Domestically this is largely a replacement market, subject to capital budget constraints and can thus fluctuate significantly year-on-year.  New business expected to replace this was not forthcoming due to delays in new product certification.  The Inspire nCPAP is considered a generic product and hence subject to pricing pressures.

 

Operating Theatre £1.7 million, +4% year on year

Revenue in this sector came back to growth after two years of decline following our decision to upgrade the patient warming system, which can also be used to enhance the LifeStart. Even though we suffered significant delay in receiving the EC certification, revenue from the AlphaCore5 enabled this sector to achieve overall growth in H2.

 

Home Healthcare £3.1 million, +15% year on year

Our Distributed Product range of parenteral feeding products continues to grow strongly in line with our expectations.

 

Gross Profit

Gross Profit of £7.0 million (FY2018: £6.8 million) increased by 4% due to a year-on-year increase in gross margin from 43.9% to 45.5%. Revenue from Inspiration Branded products, which typically generate higher gross margins than our Distributed products, increased to 46% of revenue (FY2018: 45%) or £7.2 million, thus generating a higher gross margin blend.

 

Operating Expenses

Operating expenses amounted to £5.8 million (FY2018: £5.6 million) with year-on-year increases limited to 4.4%. We made additional investment in the management team, whilst sales commission and bonus expense reduced year-on-year as not all sales targets were achieved. Depreciation and amortisation have increased by £0.1 million with amortisation of capitalised product development costs having commenced from the date the products were released to market.

 

EBITDA1

EBITDA1 amounted to £1.65 million, an increase of £0.19 million over the prior year due to increased gross profit and cash-based overheads being kept broadly flat. EBITDA margin improved from 9.4% to 10.7%.

 

1 Earnings before interest, taxation, depreciation, amortisation and share based payments ("EBITDA")

Reconciliation from operating profit

FY2019

FY2018

 

£000's

£000's

Operating Profit per Income Statement

1,213

1,204

Add back:

 

 

Depreciation and amortisation

364

230

Share based payments

71

20

EBITDA

1,648

1,454

 

Operating Profit

At £1.2 million, Operating Profit was in line with the prior year with increased gross profit offsetting slightly higher overheads.

 

 

Taxation

The Group has recorded an income tax charge of £116,000 (FY2018: credit of £21,000). This is net of current tax credits for the previous year amounting to £104,000 (FY2018: £183,000) and a related additional deferred tax charge of £56,000 (FY2018: £nil) arising from revised computations for that year. The effective tax rate in FY2019, adjusted to exclude significant prior year amendments, was 13.5% (FY2018: 13.5%) For more detail see note 3 to this announcement.

 

Earnings Per Share

EPS (basic) was 3.6p per share (FY2018: 4.0p); diluted EPS (allowing for share options outstanding) was 3.6p per share (FY2018: 4.0p). Underlying diluted EPS2 was 3.4p per share, down 2% on FY2018 (3.5p). The slight year on year declines were due to the higher net tax charge set out above.

 

2 EPS (diluted) before significant prior year tax amendments

Reconciliation from Diluted EPS

FY2019

FY2018

 

Pence

Pence

Diluted EPS as reported (see note 4)

3.56

3.98

Adjust for significant prior year tax amendments

(0.16)

(0.52)

Underlying Diluted EPS

3.40

3.46

 

Cash flow

Cash and cash equivalents as at 31 January 2019 amounted to £2.5 million, an increase of £0.45 million over the year. Net cash generated from operating activities was £0.8 million, £0.1 million lower than in FY2018. Before tax paid/recovered, cash generated from operations of £1.0 million was £0.1 million higher than FY2018. In FY2018 we received a prior year tax recovery of £0.2 million which was not repeated in FY2019. Investing activities totalled £0.4 million (FY2018: £1.0 million), primarily consisting of capitalised development expenditure of £0.3 million to complete the PWS, but lower than the £0.7 million spent in FY2018 on the same project and completing the three products that we launched towards the end of that year.

 

Net Assets

The value of Non-Current Assets as 31 January 2019 at £1.8 million was in line with FY2018 as amortisation and depreciation offset capital spend in the year. Our investment in Neuroprotexeon Ltd ("NPXe"), the drug device technology company, which represents 9.6% of the current issued share capital (8.6% fully diluted), remains unchanged and valued at cost of £111,000.

 

Inventory increased by £0.2 million to £0.7 million, primarily as a result of a depletion of inventory levels at 31 January 2018. Trade and other receivables of £3.1 million were broadly similar to the prior year, with minimal loss allowance in either year. Trade and other payables decreased by £0.5 million to £2.2 million reflecting a changed mix of products sold in January 2019 and related payment terms of the relevant suppliers, together with reduced sales commission and bonus accruals.

 

Net Assets increased by £1.2 million or 27% to £5.5 million.

 

Review of Business and Future Developments

On a Group basis the business review and future prospects are set out in the Chairman's Report above. The Board believes that overall the Annual Report and Consolidated Financial Statements are fair, balanced and understandable.

 

Share Price during the Year

The range of market prices during the year 1 February 2018 to 31 January 2019 was 47.0p to 76.0p and the mid-market price of the Company's shares at 31 January 2019 was 58.0p.

 

Mike Briant

Chief Financial Officer

30th April 2019

 

 

 

 

 

 

Consolidated Income Statement

for the year ended 31 January 2019

 

 

 

 

2019

        2018

 

 

 

Note

£'000

       £'000

 

 

 

 

 

 

 

 

Revenue

2

          15,487

     15,495

 

 

Cost of sales

 

            (8,445)

(8,709)

 

 

 

 

 

 

 

 

 

            7,042

      6,786

 

 

Operating expenses

 

            (5,829)

(5,582)

 

 

 

 

 

 

 

 

 

            1,213

               1,204

 

 

 

 

 

 

 

 

Finance income

 

                   6

           -

 

 

Finance costs

 

                     - 

             (2)

 

 

 

 

 

 

 

 

 

            1,219

      1,202

 

 

Income tax

3

               (116)  

           21

 

 

 

 

 

 

 

 

 

 

 

 

 

owners of the parent company

 

            1,103

       1,223

 

 

 

 

 

 

 

 

Earnings per share, attributable to owners of the

 

 

 

 

 

parent company

 

 

 

 

 

Basic expressed in pence per share

4

 3.60p

       3.99p

 

 

Diluted expressed in pence per share

4

3.56p

       3.98p

 

 

 

 

 

 

 

             

 

 

Consolidated Statement of Comprehensive Income

for the year ended 31 January 2019

 

 

 

 

2019

2018

 

 

 

Note

£'000

   £'000

 

 

 

 

 

 

 

Profit for the year

 

            1,103

                   1,223  

 

 

Other comprehensive expense

 

 

 

 

Items that may be reclassified to profit or loss

 

 

 

 

 

 

 

 

 

Cashflow hedges

 

                    (6)

          (3)

 

 

 

 

 

 

 

 

                    (6)

       (3)

 

 

 

 

 

 

 

 

 

               1,097

    1,220

 

 

 

 

 

 

 

 

The company has elected to take the exemption under section 408 of the Companies Act 2006 from presenting the Company profit and loss account.

Consolidated and Company Statement of Financial Position

 

as at 31 January 2019

(Registered Number: 03587944)

 

           Group

           Company

 

 

2019

           2018

         2019

 2018

 

Note

£'000

           £'000

          £'000

  £'000

 

 

 

 

 

 

Assets

 

 

 

 

 

Non-current assets

 

 

 

 

 

Intangible assets

 

          1,293

          1,209

               -

         -

Property, plant and equipment

 

             408

             461

                  -   

         -

Investments

 

             111

              111

       7,156

 7,156

Deferred tax asset

 

                 -

                  -

             11

        -

 

 

 

 

 

 

 

 

          1,812

          1,781

       7,167

 7,156

 

 

 

 

 

 

Current assets

 

 

 

 

 

Inventories

 

              718

            560

             -  

        3

Trade and other receivables

 

           3,107

         3,066

            37     

      52

Cash and cash equivalents

5

           2,539

         2,086

          675    

    668

 

 

 

 

 

 

 

 

           6,364

         5,712

          712   

    723

 

 

 

 

 

 

Total assets

 

          8,176

         7,493

       7,879 

 7,879

 

 

 

 

 

 

Liabilities

 

 

 

 

 

Current liabilities

 

 

 

 

 

Trade and other payables

 

    (2,210)

      (2,756)

          (127)

       (959)

Financial liability

 

(9)  

                 (3)

               -

        -

Contract liabilities

 

(319)

         (328)

               -

        -

 

 

 

 

 

 

 

 

(2,538)

         (3,087)

          (127)

    (959)

 

 

 

 

 

 

Non-current liabilities

 

 

 

 

 

Contract liabilities

 

                  -

                (7)

-

           -

Deferred tax liability

 

(105)

              (34)

-

        -

 

 

 

 

 

 

 

 

(105)

               (41)

-

        -

 

 

 

 

 

 

Total liabilities

 

(2,643)

          (3,128)

           (127)

    (959)

 

 

 

 

 

 

Net assets

 

          5,533

            4,365

        7,752

 6,920

 

 

 

 

 

 

Shareholders' equity

 

 

 

 

 

Called up share capital

 

          3,067

          3,067

        3,067 

 3,067

Reverse acquisition reserve

 

(16,164)

       (16,164)

              -

             -

Share based payment reserve

 

               91

              20

           246  

   175

Other reserves

 

(9)

                (3)

               -

             -

Retained earnings

 

        18,548

        17,445

        4,439

      3,678

 

 

 

 

 

 

Total equity

 

          5,533

         4,365

       7,752

 6,920

 

 

 

 

 

 

 

The Company's profit for the year ended 31 January 2019 is £761,000 (2018: loss £530,000).

 

 

 

Consolidated Statement of Changes in Shareholders' Equity

 

Group

 

 

 

 

Share

 

 

 

 

 

Issued

Share

 

Reverse

based

 

 

 

 

 

share

premium

Merger

acquisition

payment

Other

Retained

 

 

 

capital

account

reserve

reserve

reserve

Reserves

earnings

Total

 

£'000

£'000

£'000

£'000

£'000

£'000

£'000

£'000

 

 

 

 

 

 

 

 

 

 

At 1 February 2017

3,067

9,929

4,600

(16,164)

  -

            -

1,693

   3,125

 

Profit for the year

                     -

-

            -

-

-

            -

1,223

   1,223

 

Other comprehensive expense

                     -

-

            -

-

-

(3)

-

        (3)

 

 

 

 

 

 

 

 

 

 

 

Total comprehensive income/

 

 

 

 

 

 

 

 

 

(expense) for the year

                     -

-

            -

-

-

(3)

1,223

  1,220

 

 

 

 

 

 

 

 

 

 

 

Transactions with owners in

 

 

 

 

 

 

 

 

 

their capacity of owners

 

 

 

 

 

 

 

 

 

Employee share scheme expense

                     -

-

            -

-

 

 20

 

          -

-

        20

 

 

 

 

 

 

 

 

 

 

 

Capital reduction exercise:

 

 

 

 

 

 

 

 

 

- Issue of B Shares to Capitalise   Merger Reserve

4,600

-

     (4,600)

-

-

            -

-

          -

 

- Cancellation of B Shares

   (4,600)

-

            -

-

-

            -

4,600

          -

 

- Cancellation of Share Premium Account

-

        (9,929)

            -

-

-

            -

9,929

          -

 

 

 

 

 

 

 

 

 

 

 

Total transactions with owners

-

        (9,929)

     (4,600)

-

20

            -

14,529

         20

 

 

 

 

 

 

 

 

 

 

 

At 31 January 2018

3,067

-

 -

(16,164)

20

(3)

17,445

   4,365

 

Profit for the year

-

-

           -

-

-

            -

1,103

   1,103

 

Other comprehensive expense

-

-

             -

-

-

(6)

-

        (6) 

 

 

 

 

 

 

 

 

 

 

 

Total comprehensive income/

-

-

 -

                  -

-

(6)

1,103

  1,097

 

(expense) for the year

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Transactions with owners in

 

 

 

 

 

 

 

 

 

their capacity of owners

 

 

 

 

 

 

 

 

 

Employee share scheme expense

-

-

              -

-

 

71

 

             -

                  -

        71

 

 

 

 

 

 

 

 

 

 

 

Total transactions with owners

-

                -

              -

-

71

           -

                   -

         71

 

 

 

 

 

 

 

 

 

 

 

At 31 January 2019

3,067

                 -

-

(16,164)

          91

         (9)

         18,548

   5,533 

 

 

 

 

 

 

 

 

 

 

 

 

  

 

Consolidated Cash Flow Statement

 

for the year ended 31 January 2019

 

 

 

 

 

 

 

 

                 2019

          2018

 

 

Note

                £'000

          £'000

 

 

 

 

 

 

Cash flows from operating activities

 

 

 

 

Cash generated from operations

 6

                   995

            919

 

Interest paid

 

                        -

(2)

 

Taxation received

 

                        -

            161

 

Taxation paid

 

(147)

           (126)

 

 

 

 

 

 

Net cash generated from operating activities

 

                    848

            952

 

 

 

 

 

 

 

Cash flows from investing activities

 

 

 

 

 

Interest received

 

                        6

               -

Purchase of property, plant and equipment

 

(101)

           (254)

Purchase of intangible assets

 

(24)

             (68)

Capitalised development costs

 

(276)

           (688)

Acquisition of investment

 

                     -

               (5)

 

 

 

 

Net cash used in investing activities

 

(395)

        (1,015)

 

 

 

 

Cash flows from financing activities

 

 

 

 

Finance leases

 

                     -

             (16)

 

 

 

 

Net cash used in financing activities

 

                     -

             (16)

 

 

 

 

Net increase/(decrease) in cash and cash equivalents

 

                    453

             (79)

 

 

 

 

Cash and cash equivalents at the beginning of the year

 

                 2,086

         2,165

 

 

 

 

 

 

Cash and cash equivalents at the end of the year

 

                 2,539 

         2,086

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1          Accounting Policies

Inspiration Healthcare Group plc (the Company) is a public limited company incorporated in England and Wales (registration number 03587944) and domiciled in England. The Company's registered address is Unit 2, Satellite Business Village, Crawley, West Sussex, RH10 9NE and the registered company number is 03587944. The Company's ordinary shares are traded on the AIM Market of the London Stock Exchange plc.

 

The principal activities of Inspiration Healthcare Group plc and its subsidiaries (together, the "Group") continue to be the sale, service and support of critical care equipment to the medical sector including hospitals.

 

 

 

Basis of preparation

 

The principal accounting policies adopted in the preparation of these financial statements are set out below. These policies have been consistently applied unless otherwise stated.

 

There is no ultimate controlling party.

 

The individual financial statements of each entity in the Group are presented in the currency of the primary economic environment in which it operates (the functional currency). The Group financial statements are presented in pounds sterling, which is the presentation currency of the group.

 

The group had to change its accounting policies following the adoption of IFRS 9 and IFRS 15. No material impact to the accounts was noted.

 

Going concern basis

 

On the basis of current financial projections and available funds and facilities, the Directors are satisfied that the Group has adequate resources to continue in operation for the foreseeable future and, therefore, consider it appropriate to prepare the financial statements on the going concern basis. Further information on the group's cash resources is given in note 5 to this announcement.

Alternative financial measures

In the reporting of its financial performance, the Group uses certain measures that are not defined under IFRS, the Generally Accepted Accounting Principles (GAAP) under which the Group reports. The Directors believe that these non-GAAP measures assist with the understanding of the performance of the business. These non-GAAP measures are not a substitute for, or superior to, any IFRS measures of performance but they have been included as the Directors consider them to be an important means of comparing performance year-on-year and they include key measures used within the business for assessing performance.

 

2          Revenue

The group derives revenue from the transfer of goods and services over time and at a point in time in the following geographical split:

 

 

Geographical analysis of revenue for the years ended 31 January 2019 and 31 January 2018 is as follows:

 

 

 

 

 

 

 

 

 

2019

2018

 

 

 

£'000

£'000

 

 

 

 

 

Domestic

 

 

 

 

-       UK

 

 

9,772

10,338

-       Ireland

 

 

351

384

International

 

 

 

 

-     Europe

 

 

2,853

2,759

-     Asia Pacific

 

 

320

352

-     Middle East & Africa

 

 

782

795

-     Americas

 

 

1,409

867

 

 

 

 

 

 

 

15,487

15,495

 

 

 

 

 

 

 

 

 

Significant categories of revenue

 

 

 

 

 

 

 

2019

2018

 

 

 

£'000

£'000

 

 

 

 

 

Revenue recognised at a Point in Time

 

 

 

 

-       Own Branded Products

 

 

7,180

6,949

-       Distributor Products

 

 

6,341

6,500

-       Other

 

 

272

212

Revenue recognised Over Time

 

 

 

 

-       Technical Support

 

 

1,694

1,834

 

 

 

 

 

 

 

 

15,487

15,495

 

 

 

 

 

 

No single customer accounted for more than 10% of revenue.

 

The Group recognises revenue at a point in time where there is a distinct obligation to transfer goods to the customer. The Group recognises revenue over time where there is an obligation to transfer a service to the customer.

 

3          Income tax

 

 

 

 

 

 

 

(a)  Analysis of tax charge for the year

 

 

 

 

2019

     2018

 

 

£'000

     £'000

 

 

 

 

 

Domestic current year tax *

 

 

 

UK corporation tax -

 

 

 

current year

150

         145

 

prior year adjustment

                            (104)

        (187)

 

 

 

 

 

Total current tax expense/(credit)

46

          (42)

 

 

 

 

 

Deferred tax

 

 

 

    origination and reversal of temporary timing differences

14

           17

 

    prior year adjustment

56

             4

 

 

 

 

 

Total deferred tax

70

          21

 

 

 

 

 

Tax expense/(credit) on profit on ordinary activities

                            116

          (21)

 

 

 

 

 

* All tax in both 2019 and 2018 arose in the UK. 

 

 

 

(b)  Analysis of current tax assets and liabilities

 

 

 

 

2019

2018

 

 

£'000

£'000

 

 

 

 

 

Net liability at the beginning of the year

(70)

(77)

 

 

 

 

 

Tax payments

 

 

 

Final payments relating to prior year

70

50

 

Payments on account relating to current year

77

76

 

Total tax payments made during the year

147

126

 

 

 

 

 

Tax receipts in relation to prior year

-

(161)

 

 

 

 

 

Current year UK corporation tax charge

(149)

(145)

 

Other

(2)

-

 

Prior year adjustment

104

187

 

 

 

 

 

Net asset/(liability) at the end of the year

30

(70)

 

 

 

 

 

 

(c)  Factors affecting tax charge for the year

 

The tax assessed for the year is lower (2018: lower) than the standard rate of corporation tax in the UK 19.00% (2018: 19.16%) as explained below:

 

 

 

 

Effective Tax Rate

 

     2019

        2018

           2019

          2018

 

    £'000

       £'000

                %

               %

 

 

 

 

 

Profit on ordinary activities before taxation

    1,219

       1,202

 

 

Tax using the effective UK corporation tax rate of 19.00% (2018: 19.16%)

       232

           230

 

19.0

 

        19.2

Effects of:

 

 

 

 

Fixed asset differences

(5)

                -

             (0.4)

-

Non-deductible expenses

         14

               9

1.2

          0.7

Timing differences

(14)

                -

  (1.2)

-

Additional deduction for research and development

(63)

(77)

(5.1)

(6.4)

Adjustments to tax charge in respect of prior years

(48)

 (183)

(4.0)

(15.2)

Total tax expense/(credit)

       116

           (21)

 

 

Effective tax rate

 

 

            9.52

         (1.7)

Effective tax rate adjusted for significant prior year amendments

 

 

            13.5

          13.5

 

 

The effective tax rate excluding significant prior year amendments are similar for both FY2019 and FY2018. The largest factor impacting the adjusted effective tax rate is the value of R&D tax credits. This depends upon the level of expenditure incurred in research and development on qualifying projects, which may vary from year to year. Amendments in respect of prior years largely reflect the difference between the tax calculation for accounts purposes and the final tax returns. The main differences relate to claims for qualifying R&D tax credits.

 

The Research and Development Expenditure Credit (RDEC) scheme for large companies became compulsory from 1 April 2016. The RDEC provides relief against the corporation tax liability for the company of 11% on the amount of qualifying R&D expenditure.

 

Changes to the UK corporation tax rates were announced as part of the Chancellor's Budget on 16 March 2016. The change announced was to reduce the main rate of corporation tax to 17% from 1 April 2020.

 

As the change to 17% had been substantively enacted by the balance sheet date, deferred taxes at the balance sheet date have been measured using these enacted tax rates and reflected in these financial statements. 

(d)  Factors that may affect future tax charges

 

The group has gross unused losses estimated at £7,596,000. Brought forward losses transferred to the Group due to the reverse acquisition amount to £7,596,000 and are potentially available for relief against future trading profits generated from the same trade.

 

4          Earnings per ordinary share

Basic earnings per share for the year is calculated by dividing the profit attributable to ordinary shareholders for the year after tax by the weighted average number of shares in issue.

 

Basic diluted earnings per share is calculated by adjusting the weighted average number of ordinary shares in issue to assume conversion of all potential dilutive ordinary shares.

 

 

2019

         2018

 

£'000

        £'000

 

 

 

Profit

 

 

Profit attributable to equity holders of the company

1,103

1,223

 

 

 

Numerator for adjusted earnings per share calculation

1,103

1,223

 

 

 

 

 

 

The weighted average number of shares in issue and the diluted weighted average number of shares in issue were as follows:

 

 

2019

          2018

 

 

 

Shares

 

 

Weighted average number of ordinary shares in issue during the year

 

 

for the purposes of basic earnings per share

30,667,548

30,667,548

Dilutive effect of potential Ordinary shares:

 

 

share options

316,520

       66,449

 

 

 

Diluted weighted average number of shares in issue during the year

 

 

for the purposes of diluted earnings per share

30,984,068

30,733,997

 

 

 

 

 

The basic and diluted earnings per share for the year are as follows:

 

Basic

Diluted

Basic

Diluted

 

 

 

 

 

 

2019

2019

               2018

2018

 

pence

pence

             pence

pence

 

 

 

 

 

Earnings per share

           3.60

                3.56

                3.99

3.98

Adjust for:

 

 

 

 

Significant prior year tax recoveries

(0.16)

(0.16)

(0.52)

          (0.52)

Underlying earnings per share

          3.44

                3.40

                3.47

 3.46

 

 

 

 

 

 

An underlying earnings per share and a underlying diluted earnings per share have also been calculated as in the opinion of the Directors this will allow shareholders to gain a clearer understanding of the trading performance of the Group.  

 

 

5          Cash and cash equivalents

 

Cash and cash equivalents comprise solely of cash at bank and cash in hand held by the Group.

 

The carrying amounts of the Group's cash and cash equivalents are denominated in the following currencies:

 

 

Group

Company

 

2019

2018

2019

2018

 

£'000

£'000

£'000

£'000

 

 

 

 

 

Pounds sterling

1,946

1,567

664

659

Euro

328

280

6

5

US Dollars

259

236

5

4

JPY

6

3

-

-

 

 

 

 

 

Balances per statement of cashflows

2,539

2,086

675

668

 

 

 

 

 

 

 

6      Note to the Consolidated Statement of Cash Flows

 

 

 

 

 

 

2019

          2018

 

 

 

£'000

 £'000

 

 

 

 

 

 

Profit before taxation

1,219

         1,202

 

 

Adjustments for:

 

 

 

 

Net finance (Income)/Expense

                       (6)

                2

 

 

Depreciation and amortisation

364

            230

 

 

Employee share scheme expense

71

              20

 

 

Loss on disposal of tangible asset

3

              10

 

Loss on disposal of intangible asset

3

                -

 

(Increase)/Decrease in inventories

                   (158)

            218

 

Increase in trade and other receivables

                     (11)

            (575)

 

Decrease in trade and other payables

                   (474)

            (130)

 

Decrease in deferred income

                     (16)

              (58)

 

 

 

 

 

 

Cash generated from operations

995

             919

 

 

           

 

 

7      Related party transactions

 

Neuroprotexeon Limited

 

At the year-end date the Group held 9.6% (2018: 10.0%) of the issued ordinary share capital of Neuroprotexeon Limited (8.6% fully diluted (2018: 8.6%)).

 

Neil Campbell resigned as a Non-Executive Director of Neuroprotexeon Limited on 21 June 2018.

 

Key management

 

Directors control 28% of the voting shares of the legal parent company. Key management comprise the Group's Executive and Non-executive Directors.

 

 

Forward looking statements

 

Certain statements contained in this document constitute forward-looking statements. Such forward-looking statements involve risks, uncertainties and other factors which may cause the actual results, performance or achievements of Inspiration Healthcare Group plc to be materially different from any future results, performance or achievements expressed or implied by such statements. Such risks, uncertainties and other factors include, among others: general economic conditions and business environment.

 

Annual Report

 

A further announcement will be made when the 2019 Annual Report and Financial Statements are available on the Company's website (www.inspiration-healthcare.com) and copies are sent to shareholders.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FR PGUAGCUPBGCB
UK 100

Latest directors dealings